Canntab Corporate Update

TORONTO, June 30, 2022 /PRNewswire/ - Canntab Therapeutics Limited (CNSX:PILL.CN) (OTCQB:CTABF) (FRA:TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing a corporate update to its shareholders and stakeholders. Further to the announcement made by Canntab on April 14, 2022 with respect to our exploration of a variety of alternative business strategies including potential M&A opportunities, as well as identifying and negotiating partnerships to assist Canntab in expanding its product offerings in the United States and other international jurisdictions, Canntab is pleased to report that a number of discussions are now underway and the Company will provide more specific information when such information becomes material.